MedicalMinute: Next Steps Following TNF Inhibitor Failure in IBD

Learn about current guideline recommendations for therapeutic drug monitoring of TNF-α inhibitor therapy and review key data informing second-line treatment decisions of moderate to severe UC and CD following TNF-α inhibitor failure.
Bruce E. Sands, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 337 KB
Released: May 24, 2021


Provided by Clinical Care Options

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb

Related Content

On-demand webcast featuring an expert panel with insight on new data presented at ECCO 2022 for Crohn disease and ulcerative colitis from Clinical Care Options (CCO)

Uma Mahadevan, MD Bruce E. Sands, MD, MS Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: May 19, 2022 Expired: May 18, 2023

Expert slides from Clinical Care Options (CCO) on new data from ECCO 2022 17th Congress Meeting in patients with Crohn disease and ulcerative colitis

Uma Mahadevan, MD Bruce E. Sands, MD, MS Released: May 6, 2022

Downloadable slide set featuring expert guidance on therapeutic drug monitoring in IBD

Marla Dubinsky, MD Bruce E. Sands, MD, MS Released: January 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings